Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Corvus Pharmaceuticals reports Q4 loss, highlights CPI-818 potential and challenges

Corvus Pharmaceuticals showcased a mixed financial performance with a focus on managing cash burn rate and extending cash runway.
The company's strength lies in the potential of CPI-818 in various indications and the identification of a patient selection biomarker.
Challenges include cash management, regulatory hurdles in upcoming trials, and the need for clarity on biomarker validation.
Opportunities abound in market expansion, clinical development acceleration, and strategic initiatives for growth and value creation.

Corvus Pharmaceuticals reports Q1 progress with CPI-818 advancements

Corvus Pharmaceuticals reported financial improvements and progress in CPI-818 development.
Partnerships and upcoming trials indicate a promising future for the company.
Challenges lie in addressing analyst queries and ensuring trial success and data presentation.

Corvus Pharmaceuticals reports Q2 progress in cancer drug trials

Corvus Pharmaceuticals reported improved financials with reduced expenses and strategic stock sales, while advancing key drug trials in cancer treatment.
The company's focus on innovative drug development in cancer immunotherapy presents opportunities for growth and partnerships.
Challenges lie in managing expenses, conducting rigorous clinical evaluations, and balancing financial decisions with strategic priorities.

Corvus Pharmaceuticals reports Q3 progress in oncology and immune diseases

Corvus Pharmaceuticals reported a net loss of $6 million in Q3 2023 but showcased progress on soquelitinib and potential in ITK inhibition for immune diseases.
The company's financial overview and upcoming milestones indicate a strategic focus on advancing pipeline candidates and exploring partnerships.
While facing challenges in managing expenses and balancing resources, Corvus Pharmaceuticals has opportunities to drive growth through positive trial results and strategic partnerships.

Corvus Pharmaceuticals advances pipeline with promising therapies and partnerships

Corvus Pharmaceuticals showcased financial improvements and progress in their pipeline programs during Q4 2023 earnings call.
The company's focus on ITK inhibition and orphan drug designation for soquelitinib highlight their commitment to innovative therapies.
While facing cash challenges, Corvus is actively seeking partnerships and advancing trials to capitalize on commercial and medical opportunities.

Corvus Pharmaceuticals reports improved financials and promising clinical advancements

Corvus Pharmaceuticals demonstrated improved financials and strong clinical progress in Q1 2024, supported by recent financing.
The company's focus on Soquelitinib and ciforadenant presents promising opportunities for growth and advancement in the oncology space.
Challenges lie in operational scalability, trial design complexities, and the need for clear patient criteria and efficacy benchmarks.

Corvus Pharmaceuticals reports strong Q2 performance and advances key drugs

Corvus Pharmaceuticals demonstrated financial stability and clinical progress in Q2 2024, with a strong cash position and promising pipeline.
The company's focus on selective ITK inhibition for immune diseases and cancer shows commitment to innovative therapies and addressing unmet medical needs.
While facing challenges in trial expectations and resource allocation, Corvus Pharmaceuticals has opportunities for growth through portfolio diversification and milestone achievements.
Overall, Corvus Pharmaceuticals is well-positioned to capitalize on its strengths, navigate challenges, and seize opportunities in the biopharmaceutical market.

Corvus Pharmaceuticals reports Q3 losses but advances key cancer treatments

Corvus Pharmaceuticals' Q3 performance reflects increased R&D expenses but a secure financial position with available cash and potential additional funds.
The company's strengths lie in its strong pipeline, progress in key trials, and a stable financial runway into 2026 for upcoming milestones.
Challenges include addressing questions on trial specifics, competitive landscape scrutiny, and operational complexities in trial management.
Opportunities exist in advancing innovative treatments, exploring market potential, and addressing immunotherapy resistance in cancer therapy.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.

BURLINGAME, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the completion of its previously announced underwritten public offering of 9,783,660 shares of its common stock, which includes 1,212,231 shares of common stock pursuant to the underwriters' partial exercise of their option to purchase additional shares of common stock, at a price to the public of $3.50 per share. All shares in the offering were sold by Corvus, with gross proceeds to Corvus of $34.2 million and net proceeds of approximately $31.8 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock

Prothena

CollPlant Biotechnologies Ltd - ADR

Corvus Pharmaceuticals (NASDAQ: CRVS) shares are trading lower Friday after the company priced its 8.571 million share common stock offering at $3.50 per share. Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company.

Why Corvus Pharmaceuticals, Prothena, CollPlant Are Moving Today

BURLINGAME, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 8,571,429 shares of its common stock at a price to the public of $3.50 per share, for gross proceeds of $30.0 million before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by Corvus. All of the shares are being offered by Corvus. In addition, Corvus has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,285,714 shares of common stock at the public offering price, less underwriting discounts and commissions.

Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

BURLINGAME, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Corvus. In addition, Corvus expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in the offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock

Novel immunotherapy approach designed to stimulate immune response by activating B cells to enhance polyclonal antibody production and potentially reduce hospitalization and progression to respiratory failure

Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19

Updated interim d ata from CPI-818 's p hase 1/1b c linical t rial provide evidence supporting its potential as a treatment for T cell lymphomas

Corvus Presents New Data on its Investigational ITK Inhibitor CPI-818 at the American Society of Hematology (ASH) Annual Meeting & Exposition

Includes updated data from CPI-818 phase 1/1b trial and pre-clinical results supporting use in autoimmune lymphoproliferative syndrome (ALPS) Includes updated data from CPI-818 phase 1/1b trial and pre-clinical results supporting use in autoimmune lymphoproliferative syndrome (ALPS)

Corvus Announces Upcoming CPI-818 Data Presentations at the American Society of Hematology (ASH) Annual Meeting & Exposition

Data shows CPI-006 provide d enhanced and prolonged polyclonal humoral immunity to SARS - CoV - 2

Corvus Hosting R&D Symposium on November 12 to Highlight COVID-19 Program and Updated Study Data Presented at SITC Annual Meeting

Data to be presented in a poster and an oral session “ Hot Topic Symposium : COVID-19 and Cancer ” at SITC

Corvus Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Company to host R&D Symposium webcast November 12, 2020 at 11:00 am ET to highlight COVID-19 program and provide updates on its cancer programs Company to host R&D Symposium webcast November 12, 2020 at 11:00 am ET to highlight COVID-19 program and provide updates on its cancer programs

Corvus Pharmaceuticals to Present Updated Data from its Clinical Trial of CPI-006 for Patients with COVID-19 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Incyte

10X Genomics

Zai Lab Ltd.

10x Genomics acquired ReadCoor, a Boston developer of In Situ technologies, for $350 million.

Week In Review: $1.5 Billion Total In Week's China Deals

Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) shares were sharply higher on Monday after the company announced updated data from its ongoing early-stage study in patients with COVID-19.

Corvus Shareholders Must Be Happy With This COVID-19 Study Update

Angel ’s pipeline will feature Corvus’ three clinical-stage candidates – ciforadenant, CPI-006 and CPI-818 – and its preclinical BTK inhibitor program

Corvus Pharmaceuticals Announces Co-Founding of Angel Pharmaceuticals in China

Enrollment in first three cohorts complete; final cohort now enrolling with plans to initiate a pivotal study before year-end

New Data from Corvus Phase 1 Study of CPI-006 Continues to Support its Potential as a Treatment for COVID-19

Data is part of Genentech’s MORPHEUS umbrella program and covers patients with resistant/refractory NSCLC treated with ciforadenant in combination with atezolizumab

New Data from Ciforadenant Phase 1b/2 Clinical Study Presented at ESMO Virtual Congress 2020

Dr. Mitchell adds significant experience in cancer care, research and healthcare delivery as the Company advances pipeline into later-stage clinical development Dr. Mitchell adds significant experience in cancer care, research and healthcare delivery as the Company advances pipeline into later-stage clinical development

Corvus Pharmaceuticals Appoints Edith Mitchell, M.D., to Board of Directors

Characterization of novel immunotherapy approach with CPI-006 and details of COVID-19 clinical trial results submitted for publication online at medRxiv.org

Corvus Pharmaceuticals Provides Update on Clinical Trial of CPI-006 for Patients with COVID-19

BURLINGAME, Calif., Sept.  08, 2020  (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the following investor conferences:

Corvus Announces Participation in Upcoming Investor Conferences

BURLINGAME, Calif., Aug.  04, 2020  (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference. The presentation will be on Tuesday, August 11 from 2:55-3:25pm ET.

Corvus Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Provides Update on CPI-006 Phase 1 COVID-19 Study

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2020 Financial Results on July 30, 2020

VANCOUVER, British Columbia, July  16, 2020  (GLOBE NEWSWIRE) -- Corvus Gold Inc. (“Corvus Gold” or the “Company”) - (TSX: KOR, OTCQX: CORVF) announces it has received positive drilling results from its new Lynnda Strip target located approximately 2.5 kilometres to the north-northeast of the Mother Lode deposit and about half way between Mother Lode and AngloGold Ashanti’s Silicon project (Figure 1).  The Lynnda Strip mineralization is a combination of structurally and stratigraphically controlled oxide gold below approximately 150 metres of cover (Table 1).  Drill hole CH20-11 returned an oxide zone totalling 197m @ 0.44 g/t Gold including 44.2m @ 0.90 g/t Gold & 20m @ 0.74 g/t Gold.  Higher-grade intervals are associated with stockwork quartz veining hosted in volcanic rocks which is similar to the historic Bullfrog Mine and Corvus Gold’s YellowJacket gold deposits. Corvus Gold will be conducting a follow-up drill program to test the upper part of the system, which Corvus Gold projects to be higher grade.

Corvus Gold Announces Brand New Oxide Gold Discovery at the Lynnda Strip Target, 2.5 kilometres North of the Mother Lode Deposit with 44m @ 0.90 g/t Gold and 20m @ 0.74 g/t Gold within 197m @ 0.44 g/t Gold

Corvus Pharmaceuticals (CRVS) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Corvus Pharmaceuticals (CRVS) Catches Eye: Stock Jumps 8.4%

Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) made a big splash on Tuesday by announcing that it would initiate an early-stage immunotherapy study in patients with COVID-19.

Why This Analyst Sees Big Upside in COVID-19 Immunotherapy Study

Shares of Corvus (CRVS) rise as it commences a phase I study to investigate a novel immunotherapy approach for patients with COVID-19.

News for Corvus Pharmaceuticals Stock (CRVS)